Kanteti Rajani, Nallasura Vidya, Loganathan Sivakumar, Tretiakova Maria, Kroll Todd, Krishnaswamy Soundararajan, Faoro Leonardo, Cagle Philip, Husain Aliya N, Vokes Everett E, Lang Deborah, Salgia Ravi
Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA.
Lab Invest. 2009 Mar;89(3):301-14. doi: 10.1038/labinvest.2008.168. Epub 2009 Jan 12.
PAX5 is a nuclear transcription factor required for B cell development, and its expression was evaluated in upper aerodigestive malignancies and pancreatic cancer by immunoblotting. The PAX5 protein expression was relatively strong in small-cell lung cancer (SCLC, 11/12); however, its expression was not detected in non-SCLC (NSCLC, n=13), mesothelioma (n=7), pancreatic (n=6), esophageal (n=6) and head and neck cancer cell lines (n=12). In comparison, PAX8 and PAX3 expressions were absent or non-detectable in SCLC cell lines; however, PAX8 was expressed in most of the tested NSCLC cell lines (13/13) and also frequently in all the other cell lines. We also detected frequent expressions of PAX2 and PAX9 protein in the various cell lines. Utilizing neuroendocrine tumor samples, we found that the frequency as well as the average intensity of the expression of PAX5 increased from pulmonary carcinoid (9%, moderate and strong PAX5 expression, n=44), to large-cell neuroendocrine carcinoma (LCNC, 27%, n=11) to SCLC (33%, n=76). FISH analysis revealed no translocations of the PAX5 gene, but polyploidy in some SCLC tumor tissues (6/37). We determined that PAX5 could regulate the transcription of c-Met using luciferase-coupled reporter and chromatin immunoprecipitation analysis. In addition, the phospho-c-Met (active form) and PAX5 were both localized to the same intra-nuclear compartment in hepatocyte growth factor treated SCLC cells and interacted with each other. Finally, we determined the therapeutic translational potential of PAX5 using PAX5 knockdown SCLC cells in conjunction with Topoisomerase 1 (SN38) and c-Met (SU11274) inhibitors. Loss of endogenous PAX5 significantly decreased the viability of SCLC cells, especially when combined with SN38 or SU11274, and maximum effect was seen when both inhibitors were used. Therefore, we propose that PAX5 could be an important regulator of c-Met transcription and a potential target for therapy in SCLC.
PAX5是B细胞发育所需的一种核转录因子,通过免疫印迹法评估其在上消化道恶性肿瘤和胰腺癌中的表达。PAX5蛋白表达在小细胞肺癌(SCLC,11/12)中相对较强;然而,在非小细胞肺癌(NSCLC,n = 13)、间皮瘤(n = 7)、胰腺癌(n = 6)、食管癌(n = 6)和头颈癌细胞系(n = 12)中未检测到其表达。相比之下,PAX8和PAX3在SCLC细胞系中无表达或未检测到;然而,PAX8在大多数检测的NSCLC细胞系(13/13)中表达,在所有其他细胞系中也经常表达。我们还在各种细胞系中检测到PAX2和PAX9蛋白的频繁表达。利用神经内分泌肿瘤样本,我们发现PAX5表达的频率以及平均强度从肺类癌(9%,PAX5中度和强表达,n = 44)增加到大细胞神经内分泌癌(LCNC,27%,n = 11)再到SCLC(33%,n = 76)。荧光原位杂交(FISH)分析显示PAX5基因无易位,但在一些SCLC肿瘤组织中存在多倍体(6/37)。我们通过荧光素酶偶联报告基因和染色质免疫沉淀分析确定PAX5可以调节c-Met的转录。此外,在肝细胞生长因子处理的SCLC细胞中,磷酸化c-Met(活性形式)和PAX5都定位于同一核内区室并相互作用。最后,我们使用PAX5敲低的SCLC细胞结合拓扑异构酶1(SN38)和c-Met(SU11274)抑制剂来确定PAX5的治疗转化潜力。内源性PAX5的缺失显著降低了SCLC细胞的活力,尤其是与SN38或SU11274联合使用时,同时使用两种抑制剂时效果最为明显。因此,我们提出PAX5可能是c-Met转录的重要调节因子以及SCLC治疗的潜在靶点。